Wednesday, 01 March 2023

Oncology Assets for Sale

ActeaVentures has been retained by an US-company for divesting/selling its bone-targeting oncology assets. The lead compound has demonstrated efficacy in a clinical pilot study in patients with bone metastases (results compare favorably to drug of market leader in this filed).

Another preclinical project targets osteosarcoma. The company's non-bone-targeting phosphate prodrug platform is available as well.

If interested, please contact us at info@acteaventures.com and we will provide you with a non-confidential slide deck.